Pub Date : 2014-01-01DOI: 10.1080/20742835.2014.11441227
A. Mukherji, S. Vivekanandham, K. S. Reddy
Cervical cancer is the third most commonly diagnosed cancer, and the fourth leading cause of cancer deaths in women worldwide. In 2008, there were an estimated 529 000 new cases of cervical cancer, and 275 000 cervical cancer-related deaths. 1 Cancer of the cervix has been the most common cancer in women in India for the past two decades. 2 The lungs, para-aortic lymph nodes and supraclavicular nodes are the most common sites of distant metastases. Bone metastases are not commonly seen, usually only in 0.8-23% of cases, and then mostly in the dorsal or lumbar vertebrae. 3,4 Skeletal deposits were estimated to occur in less than 1% of patients in postmortem reports of large series of cases, such as those compiled by MacCormack. 5 Matsuyama, Tsukamoto, Imachi and Nakano reported rates as high as 4-6.5%. 6 Large fungating or invasive lesions are rarely seen since the advent of the routine use of screening procedures for cervical cancer in the Western world. However, such lesions are still commonly observed in developing countries. We describe a case of locally advanced cervical cancer, which had spread laterally to involve the left pelvic side wall, causing erosion and destruction of the left acetabulum and femoral head.
{"title":"Case of a locally advanced carcinoma cervix presenting with protrusio acetabuli: pre-screening era presentation rarely seen in modern times","authors":"A. Mukherji, S. Vivekanandham, K. S. Reddy","doi":"10.1080/20742835.2014.11441227","DOIUrl":"https://doi.org/10.1080/20742835.2014.11441227","url":null,"abstract":"Cervical cancer is the third most commonly diagnosed cancer, and the fourth leading cause of cancer deaths in women worldwide. In 2008, there were an estimated 529 000 new cases of cervical cancer, and 275 000 cervical cancer-related deaths. 1 Cancer of the cervix has been the most common cancer in women in India for the past two decades. 2 \u0000 \u0000The lungs, para-aortic lymph nodes and supraclavicular nodes are the most common sites of distant metastases. Bone metastases are not commonly seen, usually only in 0.8-23% of cases, and then mostly in the dorsal or lumbar vertebrae. 3,4 Skeletal deposits were estimated to occur in less than 1% of patients in postmortem reports of large series of cases, such as those compiled by MacCormack. 5 Matsuyama, Tsukamoto, Imachi and Nakano reported rates as high as 4-6.5%. 6 \u0000 \u0000Large fungating or invasive lesions are rarely seen since the advent of the routine use of screening procedures for cervical cancer in the Western world. However, such lesions are still commonly observed in developing countries. We describe a case of locally advanced cervical cancer, which had spread laterally to involve the left pelvic side wall, causing erosion and destruction of the left acetabulum and femoral head.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"6 1","pages":"33 - 35"},"PeriodicalIF":0.3,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2014.11441227","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60046860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01DOI: 10.1080/20742835.2014.11441225
D. Babu, Abhishek Maheshwari, M. Sengar, S. Menon
Rosai-Dorfman disease, also termed sinus histiocytosis with massive lymphadenopathy (SHML), represents a rare proliferative disorder of histiocytes, that commonly affects the cervical lymph nodes. It was first described as a unique clinicopathological entity by Rosai and Dorfman in 1969. 1 Extranodal disease is encountered in almost half of all cases, presenting within the skin, soft tissue, salivary glands, bone or central nervous system. We describe a case of a young female who presented with an iliac fossa mass. Radiological imaging failed to demonstrate abnormalities within the uterus or the adnexae. A biopsy of the mass revealed sinus histiocytosis with emperipolesis, consistent with a diagnosis of Rosai-Dorfman disease. The patient was treated with conventional chemotherapy, followed by surgical intervention in the form of complete pelvic lymph node clearance. The patient has remained disease free to date.
{"title":"A case study on Rosai-Dorfman disease occurring within the pelvis","authors":"D. Babu, Abhishek Maheshwari, M. Sengar, S. Menon","doi":"10.1080/20742835.2014.11441225","DOIUrl":"https://doi.org/10.1080/20742835.2014.11441225","url":null,"abstract":"Rosai-Dorfman disease, also termed sinus histiocytosis with massive lymphadenopathy (SHML), represents a rare proliferative disorder of histiocytes, that commonly affects the cervical lymph nodes. It was first described as a unique clinicopathological entity by Rosai and Dorfman in 1969. 1 Extranodal disease is encountered in almost half of all cases, presenting within the skin, soft tissue, salivary glands, bone or central nervous system. We describe a case of a young female who presented with an iliac fossa mass. Radiological imaging failed to demonstrate abnormalities within the uterus or the adnexae. A biopsy of the mass revealed sinus histiocytosis with emperipolesis, consistent with a diagnosis of Rosai-Dorfman disease. The patient was treated with conventional chemotherapy, followed by surgical intervention in the form of complete pelvic lymph node clearance. The patient has remained disease free to date.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"6 1","pages":"27 - 29"},"PeriodicalIF":0.3,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2014.11441225","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60046777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01DOI: 10.1080/20742835.2014.11441221
L. V. van Bogaert
I read with interest the case report on invasive adenocarcinoma of the cervix in a human immunodeficiency virus (HIV) and schistosome co-infected patient. I would like to make some comments. Schistosomiasis is endemic in Limpopo, Mpumalanga and KwaZulu-Natal. Prevention rests on two legs: water sanitation and the screening of schoolchildren. Because of the high cost of water sanitation, the main preventive measure is screening and treatment at school level. Unfortunately, no systematic prevention programme has been implemented in South Africa.
{"title":"Case of invasive adenocarcinoma of the cervix in a human immunodeficiency virus and schistosome co-infected patient","authors":"L. V. van Bogaert","doi":"10.1080/20742835.2014.11441221","DOIUrl":"https://doi.org/10.1080/20742835.2014.11441221","url":null,"abstract":"I read with interest the case report on invasive adenocarcinoma of the cervix in a human immunodeficiency virus (HIV) and schistosome co-infected patient. I would like to make some comments. Schistosomiasis is endemic in Limpopo, Mpumalanga and KwaZulu-Natal. Prevention rests on two legs: water sanitation and the screening of schoolchildren. Because of the high cost of water sanitation, the main preventive measure is screening and treatment at school level. Unfortunately, no systematic prevention programme has been implemented in South Africa.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"6 1","pages":"5 - 6"},"PeriodicalIF":0.3,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2014.11441221","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60046616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01DOI: 10.1080/20742835.2014.11441226
G. du Toit
2014 Vol 6 No 1 South Afr J Gynaecol Oncol Du Toit GC, MBChB, MMed, FCOG(SA), Part-Time Consultant Unit of Gynaecological Oncology, Tygerberg Hospital, University of Stellenbosch, Stellenbosch Correspondence to: George du Toit, e-mail: dutoitg@worldonline.co.za
2014年第6卷第1期《南非妇科肿瘤杂志》，GC，MBChB，MMed，FCOG（SA），妇科肿瘤兼职顾问单位，斯泰伦堡大学泰格堡医院，斯泰伦博斯通信：George Du Toit，电子邮件：dutoitg@worldonline.co.za
{"title":"Fertility-sparing treatment in a young patient with complex atypical hyperplasia of the endometrium","authors":"G. du Toit","doi":"10.1080/20742835.2014.11441226","DOIUrl":"https://doi.org/10.1080/20742835.2014.11441226","url":null,"abstract":"2014 Vol 6 No 1 South Afr J Gynaecol Oncol Du Toit GC, MBChB, MMed, FCOG(SA), Part-Time Consultant Unit of Gynaecological Oncology, Tygerberg Hospital, University of Stellenbosch, Stellenbosch Correspondence to: George du Toit, e-mail: dutoitg@worldonline.co.za","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"6 1","pages":"30 - 32"},"PeriodicalIF":0.3,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2014.11441226","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60046788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01DOI: 10.1080/20742835.2014.11441222
Peter Liptak, R. Barnetson
Abstract Sampling for histological examination is usually part of the work-up for further planning with regard to the management of patients presenting with uterine bleeding. This review, utilising the classification of the World Health Organization, aims to discuss some commonly recurring differential diagnostic problems on small biopsy specimens. Diagnostic difficulties generally relate to representativeness of the sample, determining the site of the lesion, and fragmentation and trauma artefact. Reference is made to clinical relevance, and attention drawn to some lesser known diagnostic entities. Morphological features and immunohistochemical markers that are useful in certain differential diagnostic scenarios are highlighted. The level of diagnostic certainty should be indicated in the report, and when the limitations do not permit a definite diagnosis in a small sample, the pathologist should provide the clinician with a differential diagnosis on which further management decisions can be based.
{"title":"Small biopsy pathology of mass lesions of the endometrial cavity: differential diagnostic considerations","authors":"Peter Liptak, R. Barnetson","doi":"10.1080/20742835.2014.11441222","DOIUrl":"https://doi.org/10.1080/20742835.2014.11441222","url":null,"abstract":"Abstract Sampling for histological examination is usually part of the work-up for further planning with regard to the management of patients presenting with uterine bleeding. This review, utilising the classification of the World Health Organization, aims to discuss some commonly recurring differential diagnostic problems on small biopsy specimens. Diagnostic difficulties generally relate to representativeness of the sample, determining the site of the lesion, and fragmentation and trauma artefact. Reference is made to clinical relevance, and attention drawn to some lesser known diagnostic entities. Morphological features and immunohistochemical markers that are useful in certain differential diagnostic scenarios are highlighted. The level of diagnostic certainty should be indicated in the report, and when the limitations do not permit a definite diagnosis in a small sample, the pathologist should provide the clinician with a differential diagnosis on which further management decisions can be based.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"6 1","pages":"14 - 7"},"PeriodicalIF":0.3,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2014.11441222","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60046664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01DOI: 10.1080/20742835.2014.11441224
N. Heunis, A. Horton, K. Richter, G. Dreyer, M. Louw
Abstract Background: The L1 capsid protein is a viral nuclear protein that encapsidates the human papillomavirus (HPV) DNA to build new infectious particles. Previous studies in immune-competent patients have shown that detectable L1 protein in lowgrade squamous intraepithelial lesion (LSIL) smears is associated with remission in 60–75% of cases. Thus, the test can reduce interventions by approximately 75%. Objective: This study was performed to evaluate the use of HPV L1 capsid protein detection on cytology samples in a population with relatively high human immunodeficiency virus (HIV) prevalence and with known high-risk HPV (hrHPV) DNA results. Setting: Samples were obtained during a cervical cancer screening study at primary healthcare clinics in the Tshwane district, Gauteng. The HIV prevalence of the target group was estimated to be between 20% and 30%. Method: Conventional cervical cytology smears of 575 women were microscopically assessed and diagnosed. In addition, women were tested for the presence of HPV DNA on a cervical or vaginal sample. Immunocytochemical analysis was performed on morphologically abnormal smears and on a 52 control group smears reported to be negative for HPV DNA and morphological abnormalities. The detection of L1 capsid protein was carried out with the Cytoactiv® HPV L1 screening set, an antibody-based immunocytochemical stain. Results: A cytological diagnosis of LSIL was made in 19 women (3.3%), high-grade squamous intraepithelial lesions (HSILs) in 42 (7.5%) and malignancy in 1 (0.2%). Of the LSIL cases, 10 of 19 (52.6%) stained positive for the presence of the L1 protein, while only one of 42 HSIL (2.4%) cases stained positive. Three hundred and four cases (52.9%) tested positive for hrHPV DNA, including women with LSIL, HSIL and malignancy. All of the control cases stained negative for the L1 capsid protein. Conclusion: hrHPV was not a useful triage test for women with abnormal cellular morphology in this population. Promising results were reported for Cytoactiv® immunostaining as a triage test for patients with LSIL, but it added no value to samples known to be HPV-negative or reported to be morphologically negative. The immunostaining of smears reported to be HSIL or worse were almost universally negative, supporting the diagnostic accuracy of cytology and the expectation of persistence or progression of these lesions.
{"title":"HPV L1 capsid protein detection in high-risk human papillomavirus-positive cervical smears","authors":"N. Heunis, A. Horton, K. Richter, G. Dreyer, M. Louw","doi":"10.1080/20742835.2014.11441224","DOIUrl":"https://doi.org/10.1080/20742835.2014.11441224","url":null,"abstract":"Abstract Background: The L1 capsid protein is a viral nuclear protein that encapsidates the human papillomavirus (HPV) DNA to build new infectious particles. Previous studies in immune-competent patients have shown that detectable L1 protein in lowgrade squamous intraepithelial lesion (LSIL) smears is associated with remission in 60–75% of cases. Thus, the test can reduce interventions by approximately 75%. Objective: This study was performed to evaluate the use of HPV L1 capsid protein detection on cytology samples in a population with relatively high human immunodeficiency virus (HIV) prevalence and with known high-risk HPV (hrHPV) DNA results. Setting: Samples were obtained during a cervical cancer screening study at primary healthcare clinics in the Tshwane district, Gauteng. The HIV prevalence of the target group was estimated to be between 20% and 30%. Method: Conventional cervical cytology smears of 575 women were microscopically assessed and diagnosed. In addition, women were tested for the presence of HPV DNA on a cervical or vaginal sample. Immunocytochemical analysis was performed on morphologically abnormal smears and on a 52 control group smears reported to be negative for HPV DNA and morphological abnormalities. The detection of L1 capsid protein was carried out with the Cytoactiv® HPV L1 screening set, an antibody-based immunocytochemical stain. Results: A cytological diagnosis of LSIL was made in 19 women (3.3%), high-grade squamous intraepithelial lesions (HSILs) in 42 (7.5%) and malignancy in 1 (0.2%). Of the LSIL cases, 10 of 19 (52.6%) stained positive for the presence of the L1 protein, while only one of 42 HSIL (2.4%) cases stained positive. Three hundred and four cases (52.9%) tested positive for hrHPV DNA, including women with LSIL, HSIL and malignancy. All of the control cases stained negative for the L1 capsid protein. Conclusion: hrHPV was not a useful triage test for women with abnormal cellular morphology in this population. Promising results were reported for Cytoactiv® immunostaining as a triage test for patients with LSIL, but it added no value to samples known to be HPV-negative or reported to be morphologically negative. The immunostaining of smears reported to be HSIL or worse were almost universally negative, supporting the diagnostic accuracy of cytology and the expectation of persistence or progression of these lesions.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"6 1","pages":"22 - 26"},"PeriodicalIF":0.3,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2014.11441224","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60046721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-01DOI: 10.1080/20742835.2014.11441223
T. de Greve, L. Snyman
Abstract Cervical cancer is the second most common cancer in southern African women. Although the FIGO staging does not include lymph node status, lymph node metastasis is an important risk factor for recurrence and death in patients with early cervical cancer. Accurate information about lymph node metastasis is crucial to decide on optimal individualised treatment. Complete pelvic lymphadenectomy is the current standard used to obtain accurate information on lymph node status. Because of the low incidence of nodal metastasis in patients with early cervical cancer, identifying women in whom lymphadenectomy can be safely avoided would result in less morbidity associated with pelvic lymphadenectomy, without compromising overall and disease-free survival. Over the past 15 years, the role of sentinel lymph node (SLN) biopsy has been studied extensively in patients with early-stage cervical cancer. Assessment of the SLN in women with early-stage disease may potentially offer an alternative to complete lymphadenectomy. Data are limited with regard to the role of SLN assessment in patients with cervical cancer in low-resource settings where the prevalence of HIV and other gynaecological infections is high.
{"title":"The role of sentinel lymph node biopsy in cervical cancer: an overview of the literature","authors":"T. de Greve, L. Snyman","doi":"10.1080/20742835.2014.11441223","DOIUrl":"https://doi.org/10.1080/20742835.2014.11441223","url":null,"abstract":"Abstract Cervical cancer is the second most common cancer in southern African women. Although the FIGO staging does not include lymph node status, lymph node metastasis is an important risk factor for recurrence and death in patients with early cervical cancer. Accurate information about lymph node metastasis is crucial to decide on optimal individualised treatment. Complete pelvic lymphadenectomy is the current standard used to obtain accurate information on lymph node status. Because of the low incidence of nodal metastasis in patients with early cervical cancer, identifying women in whom lymphadenectomy can be safely avoided would result in less morbidity associated with pelvic lymphadenectomy, without compromising overall and disease-free survival. Over the past 15 years, the role of sentinel lymph node (SLN) biopsy has been studied extensively in patients with early-stage cervical cancer. Assessment of the SLN in women with early-stage disease may potentially offer an alternative to complete lymphadenectomy. Data are limited with regard to the role of SLN assessment in patients with cervical cancer in low-resource settings where the prevalence of HIV and other gynaecological infections is high.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"6 1","pages":"15 - 21"},"PeriodicalIF":0.3,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2014.11441223","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60046703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-01-01DOI: 10.1080/20742835.2013.11441207
V. Sewram
The African Organisation for Research and Training in Cancer (AORTIC) will be holding its 9th International Cancer Conference entitled “Cancer in Africa: Bridging Science and Humanity” at the Durban International Convention Centre from 21-24 November 2013.
{"title":"Cancer in Africa: Bridging Science and Humanity","authors":"V. Sewram","doi":"10.1080/20742835.2013.11441207","DOIUrl":"https://doi.org/10.1080/20742835.2013.11441207","url":null,"abstract":"The African Organisation for Research and Training in Cancer (AORTIC) will be holding its 9th International Cancer Conference entitled “Cancer in Africa: Bridging Science and Humanity” at the Durban International Convention Centre from 21-24 November 2013.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"5 1","pages":"39 - 40"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2013.11441207","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60046685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-01-01DOI: 10.1080/20742835.2013.11441213
L. Snyman
In 2009, The Cancer Association of South Africa (CANSA) awarded its biggest research grant to date to the HPV Cervical Cancer Research Fund, under the auspices of Prof Greta Dreyer. This grant enabled a group of researchers from different disciplines to conduct a project to investigate large-scale cervical cancer screening of peri-urban women using cytology and molecular testing. The main findings of this study, performed in the Tshwane Health District, are reported in this supplement which is introduced by Dr Carl Albrecht, Head of Research, CANSA.
{"title":"About this supplement…","authors":"L. Snyman","doi":"10.1080/20742835.2013.11441213","DOIUrl":"https://doi.org/10.1080/20742835.2013.11441213","url":null,"abstract":"In 2009, The Cancer Association of South Africa (CANSA) awarded its biggest research grant to date to the HPV Cervical Cancer Research Fund, under the auspices of Prof Greta Dreyer. This grant enabled a group of researchers from different disciplines to conduct a project to investigate large-scale cervical cancer screening of peri-urban women using cytology and molecular testing. The main findings of this study, performed in the Tshwane Health District, are reported in this supplement which is introduced by Dr Carl Albrecht, Head of Research, CANSA.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"5 1","pages":"S2 - S2"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2013.11441213","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60046859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-01-01DOI: 10.1080/20742835.2013.11441218
M. V. van Aardt, G. Dreyer, K. Richter, P. Becker
Abstract Objectives: Knowledge of human papillomavirus (HPV) distribution in the general population is crucial for the development of new HPV vaccines and to provide a baseline from which to monitor the impact of current HPV vaccines in the future. HPV-type distribution in the Tshwane area, South Africa, might be different to that in other regions and countries. Design: This was a retrospective descriptive study, representative of women without cervical cytological abnormalities. Setting and subjects: Women attending primary health clinics in the region of Tshwane were screened for cervical abnormalities with conventional cytology. Outcome measures: Women without cytological abnormalities were included, and HPV DNA typing, using HPV Linear® Array Genotyping Test (Roche Molecular Systems, Branchburg, USA) was performed on all women. Results: Demographic data were available for 1 238 patients. The mean age was 40.9 years. The majority of the women (14.6%) were between 35 and 39 years of age. 19.4% of women were younger than 30 years of age. The prevalence of HPV types was 67.1% and high-risk HPV infections, 44.9%. The average number of HPV-type infections was 3.2 in the 845 patients with HPV infections. The most common high-risk virus was HPV 16 (10.8%), followed by HPV 51 (9.3%), and HPV 58 (7.9%). HPV 18 was observed in 5.9%, and HPV 45 in 7.5%, of participants. HPV 62 (15.6%) and HPV 84 (14.4%) were the most prevalent low-risk types. Conclusion: HPV infections were highly prevalent in this population. The prevalence of HPV 16 and 18 was higher than that reported in other world regions. HPV 16 was the most prevalent high-risk type infection in women without cytological abnormalities. HPV infections other than HPV 16 and 18 were also prevalent, and this is important for future vaccine development.
{"title":"Human papillomavirus-type distribution in South African women without cytological abnormalities: a peri-urban study","authors":"M. V. van Aardt, G. Dreyer, K. Richter, P. Becker","doi":"10.1080/20742835.2013.11441218","DOIUrl":"https://doi.org/10.1080/20742835.2013.11441218","url":null,"abstract":"Abstract Objectives: Knowledge of human papillomavirus (HPV) distribution in the general population is crucial for the development of new HPV vaccines and to provide a baseline from which to monitor the impact of current HPV vaccines in the future. HPV-type distribution in the Tshwane area, South Africa, might be different to that in other regions and countries. Design: This was a retrospective descriptive study, representative of women without cervical cytological abnormalities. Setting and subjects: Women attending primary health clinics in the region of Tshwane were screened for cervical abnormalities with conventional cytology. Outcome measures: Women without cytological abnormalities were included, and HPV DNA typing, using HPV Linear® Array Genotyping Test (Roche Molecular Systems, Branchburg, USA) was performed on all women. Results: Demographic data were available for 1 238 patients. The mean age was 40.9 years. The majority of the women (14.6%) were between 35 and 39 years of age. 19.4% of women were younger than 30 years of age. The prevalence of HPV types was 67.1% and high-risk HPV infections, 44.9%. The average number of HPV-type infections was 3.2 in the 845 patients with HPV infections. The most common high-risk virus was HPV 16 (10.8%), followed by HPV 51 (9.3%), and HPV 58 (7.9%). HPV 18 was observed in 5.9%, and HPV 45 in 7.5%, of participants. HPV 62 (15.6%) and HPV 84 (14.4%) were the most prevalent low-risk types. Conclusion: HPV infections were highly prevalent in this population. The prevalence of HPV 16 and 18 was higher than that reported in other world regions. HPV 16 was the most prevalent high-risk type infection in women without cytological abnormalities. HPV infections other than HPV 16 and 18 were also prevalent, and this is important for future vaccine development.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"5 1","pages":"S21 - S27"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2013.11441218","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60047054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：